Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 14, 2008

 

 

Pharmasset, Inc.

(Exact Name of Issuer as Specified in Charter)

 

 

 

Delaware   001-33428   98-0406340

(State or Other Jurisdiction of

Incorporation or Organization)

   (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

303-A College Road East

Princeton, New Jersey

   08540
(Address of Principal Executive Offices)   (Zip Code)

(609) 613-4100

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 

 

Item 8.01. Other Events.

On May 14, 2008, Pharmasset, Inc. (the “Company”) issued a press release announcing the commencement of dosing of the third and fourth cohorts of an on-going Phase 1 study of R7128, a product candidate the Company is developing with Roche for the treatment of hepatitis C. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) The following exhibit relating to Item 8.01 is furnished with this report on Form 8-K:

 

99.1 Press Release of Pharmasset, Inc. dated May 14, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pharmasset, Inc.
Date: May 15, 2008   By:  

/s/ Kurt Leutzinger

    Kurt Leutzinger
    Chief Financial Officer

EXHIBIT INDEX

 

Exhibit

Number

  

Exhibit

99.1   Press Release of Pharmasset, Inc. dated May 14, 2008.